InterPAD - DETAILS

Lenvatinib, 417716-92-8, E7080, 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, E7080 (Lenvatinib), Lenvatinib (E7080), E-7080, ER-203492-00, E 7080, Lenvatinib free base, Kisplyx, UNII-EE083865G2, 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide, CHEBI:85994, EE083865G2, 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide, CHEMBL1289601, DTXSID50194605, 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, 417716-92-8 (free base), 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide, 4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE, N-(4-((6-CARBAMOYL-7-METHOXYQUINOLIN-4-YL)OXY)-2-CHLOROPHENYL)-N'-CYCLOPROPYLUREA, 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-, Lenvatinib [USAN], Lenvatinib [USAN:INN], lenvatinibum, C21H19ClN4O4, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; E 7080; ER 203492-00; Lenvatinib; Lenvima, LEV, Lenvatinib; E7080, LENVATINIB [MI], Lenvatinib base- Bio-X, LENVATINIB [INN], Lenvatinib (USAN/INN), LENVATINIB [WHO-DD], MLS006011239, SCHEMBL864638, GTPL7426, Multi-Kinase Inhibitor E7080, AMY9240, DTXCID50117096, EX-A249, L01XE29, WOSKHXYHFSIKNG-UHFFFAOYSA-N, BCPP000247, HMS3244A07, HMS3244A08, HMS3244B07, HMS3654A14, BCP01799, BDBM50331094, MFCD16038644, NSC755980, NSC800781, s1164, AKOS025401742, BCP9000633, CCG-264842, CS-0109, DB09078, NSC-755980, NSC-800781, SB16580, NCGC00263198-01, NCGC00263198-04, NCGC00263198-07, AC-25047, AS-16203, BL164616, HY-10981, SMR004702999, DB-070219, FT-0700727, NS00069283, SW219259-1, D09919, EN300-7418350, A825653, J-513372, Q6523413, BRD-K39974922-001-02-7, Z2235801899, 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide, 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide, 6-Quinolinecarboxamide, 4-(3-chloro-4- (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-, 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)- 7-METHOXY-

No.	Title	Href
1	Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. PeerJ. 2023 Jan 25;11:e14610. doi: 10.7717/peerj.14610.	`Click`
2	Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells. 2023;12(4):612. Published 2023 Feb 14. doi:10.3390/cells12040612.	`Click`

No.

Title

Href

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. PeerJ. 2023 Jan 25;11:e14610. doi: 10.7717/peerj.14610. 

Click

Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells. 2023;12(4):612. Published 2023 Feb 14. doi:10.3390/cells12040612.

Click

Name	Lenvatinib
PubChem CID	9823820
Molecular Weight	426.9g/mol
Synonyms	Lenvatinib, 417716-92-8, E7080, 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, E7080 (Lenvatinib), Lenvatinib (E7080), E-7080, ER-203492-00, E 7080, Lenvatinib free base, Kisplyx, UNII-EE083865G2, 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide, CHEBI:85994, EE083865G2, 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide, CHEMBL1289601, DTXSID50194605, 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, 417716-92-8 (free base), 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide, 4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE, N-(4-((6-CARBAMOYL-7-METHOXYQUINOLIN-4-YL)OXY)-2-CHLOROPHENYL)-N'-CYCLOPROPYLUREA, 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-, Lenvatinib [USAN], Lenvatinib [USAN:INN], lenvatinibum, C21H19ClN4O4, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; E 7080; ER 203492-00; Lenvatinib; Lenvima, LEV, Lenvatinib; E7080, LENVATINIB [MI], Lenvatinib base- Bio-X, LENVATINIB [INN], Lenvatinib (USAN/INN), LENVATINIB [WHO-DD], MLS006011239, SCHEMBL864638, GTPL7426, Multi-Kinase Inhibitor E7080, AMY9240, DTXCID50117096, EX-A249, L01XE29, WOSKHXYHFSIKNG-UHFFFAOYSA-N, BCPP000247, HMS3244A07, HMS3244A08, HMS3244B07, HMS3654A14, BCP01799, BDBM50331094, MFCD16038644, NSC755980, NSC800781, s1164, AKOS025401742, BCP9000633, CCG-264842, CS-0109, DB09078, NSC-755980, NSC-800781, SB16580, NCGC00263198-01, NCGC00263198-04, NCGC00263198-07, AC-25047, AS-16203, BL164616, HY-10981, SMR004702999, DB-070219, FT-0700727, NS00069283, SW219259-1, D09919, EN300-7418350, A825653, J-513372, Q6523413, BRD-K39974922-001-02-7, Z2235801899, 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide, 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide, 6-Quinolinecarboxamide, 4-(3-chloro-4- (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-, 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)- 7-METHOXY-
Drug Type	Small molecule
Formula	C₂₁H₁₉ClN₄O₄
SMILES	COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
InChI	1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
InChIKey	WOSKHXYHFSIKNG-UHFFFAOYSA-N
CAS Number	417716-92-8
ChEMBL ID	CHEMBL1289601
ChEBI ID	CHEBI:85994
TTD ID	D0R0FO
Drug Bank ID	DB09078
KEGG ID	D09919
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Vitamin C, Lenvatinib
Partner Name	Vitamin C
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Cell proliferative, migratory and invasive capacities
Gene Regulation	Down-regulation	Expression	MET	hsa4233
In Vitro Model	Hep 3B2.1-7	Childhood hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0326
	Huh-7	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0336
	SK-HEP-1	Liver and intrahepatic bile duct epithelial neoplasm	Homo sapiens (Human)	CVCL_0525
Result	Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro

Pair Name	Curcumin, Lenvatinib
Partner Name	Curcumin
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Expression	EGFR	hsa1956
	Down-regulation	Expression	MTOR	hsa2475
In Vitro Model	Huh-7	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0336
	SNU-449	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0454
	PLC/PRF/5	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0485
	SNU-398	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0077
	SK-HEP-1	Liver and intrahepatic bile duct epithelial neoplasm	Homo sapiens (Human)	CVCL_0525
Result	We report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC.